Mucolipidosis IV (MLIV) is an autosomal-recessive disease caused by loss-of-function mutations in the MCOLN1 gene encoding the non-selective cationic lysosomal channel transient receptor potential mucolipin-1 (TRPML1). Patients with MLIV suffer from severe motor and cognitive deficits that manifest in early infancy and progressive loss of vision leading to blindness in the second decade of life. There are no therapies available for MLIV and the unmet medical need is extremely high. Here we review the spectrum of clinical presentations and the latest research in the MLIV pre-clinical model, with the aim of highlighting the progress in understanding the pathophysiology of the disease. These highlights include elucidation of the neurodevelopmental versus neurodegenerative features over the course of disease, hypomyelination as one of the major brain pathological disease hallmarks, and dysregulation of cytokines, with emerging evidence of IFN-gamma pathway upregulation in response to TRPML1 loss and pro-inflammatory activation of astrocytes and microglia. These scientific advances in the MLIV field provide a basis for future translational research, including biomarker and therapy development, that are desperately needed for this patient population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253105 | PMC |
| http://dx.doi.org/10.1016/j.neulet.2021.135944 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the impact of variations in the mucolipin1 protein that result in mucolipidosis type 4 using the technique of molecular docking and dynamics simulation.
J Biomol Struct Dyn
December 2024
Department of Biotechnology, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, India.
Mucolipidosis type IV (MLIV) is classified as an exceptionally autosomal recessive condition due to a change in MCOLN1 that encodes the mucolipin-1 protein. ML-1 is a membrane protein comprising 6 Trans regions, which are situated at the LELs, a serine lipase area, and a nuclear localization sign. The characteristic features of the ML4 patients are mental retardation and skeletal deformities due to an increase in lipid molecules in the brain, other tissues, and organs.
View Article and Find Full Text PDFTRPML-1 Dysfunction and Renal Tubulopathy in Mucolipidosis Type IV.
J Am Soc Nephrol
December 2024
Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Naples, Italy.
Article Synopsis
- * A study reviewed 21 MLIV patients and conducted experiments on MLIV mouse models to understand kidney function, revealing that adult patients often have chronic kidney disease along with altered kidney functions and structure in the mice due to issues with endolysosomal function and autophagy.
- * Results showed decreased kidney function, presence of fibrosis and inflammation in MLIV models, and impaired uptake of essential proteins, which highlights cellular and systemic dysfunction in the
TRPML1 gating modulation by allosteric mutations and lipids.
Elife
October 2024
Howard Hughes Medical Institute and Department of Physiology, University of Texas Southwestern Medical Center, Dallas, United States.
Article Synopsis
- Transient Receptor Potential Mucolipin 1 (TRPML1) is a lysosomal channel, and mutations in it lead to mucolipidosis type IV (MLIV), a lysosomal storage disorder.
- The study pinpointed a key residue, Tyr404, which, when mutated, alters the channel's function, mimicking ligand effects without disrupting binding, making these mutants useful for drug screening.
- Researchers also detailed the high-resolution structure of TRPML1 with an inhibitor, identifying a potential lipid that explains how sphingomyelin inhibits the channel's activation by agonists.
TRPML1 gating modulation by allosteric mutations and lipids.
bioRxiv
September 2024
Howard Hughes Medical Institute and Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Transient Receptor Potential Mucolipin 1 (TRPML1) is a lysosomal cation channel whose loss-of-function mutations directly cause the lysosomal storage disorder mucolipidosis type IV (MLIV). TRPML1 can be allosterically regulated by various ligands including natural lipids and small synthetic molecules and the channel undergoes a global movement propagated from ligand-induced local conformational changes upon activation. In this study, we identified a functionally critical residue, Tyr404, at the C-terminus of the S4 helix, whose mutations to tryptophan and alanine yield gain- and loss-of-function channels, respectively.
View Article and Find Full Text PDFA blood-brain barrier-penetrant AAV gene therapy improves neurological function in symptomatic mucolipidosis IV mice.
Mol Ther Methods Clin Dev
June 2024
Center for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute and Harvard Medical School, 185 Cambridge St, Boston, MA 02114, USA.
Article Synopsis
- * Researchers have developed a new gene expression vector, CPP16, which effectively delivered the human gene responsible for MLIV in preclinical mouse models.
- * The treatment improved brain function and motor skills, preventing paralysis, although it did not restore retinal thickness despite some positive effects on retinal tissue degeneration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!